Noninvasive detection of temozolomide in brain tumor xenografts by magnetic resonance spectroscopy

Neuro-Oncology

Volumn 12, Issue 1, 2010, Pages 71-79

  Kato, Yoshinori ^a   Holm, David A ^b,c   Okollie, Baasil ^a   Artemov, Dmitri ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Brain tumor; Drug detection; MR imaging; MR spectroscopy; Temozolomide

Indexed keywords

GADOLINIUM PENTETATE; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; TEMOZOLOMIDE C 13; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BLOOD FLOW; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DETERMINATION; DRUG UPTAKE; GLIOBLASTOMA; HETERONUCLEAR MULTIPLE QUANTUM COHERENCE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; THREE DIMENSIONAL IMAGING; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; VASCULAR TUMOR; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CARBON RADIOISOTOPES; CELL LINE, TUMOR; DACARBAZINE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MICE; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 75749133188     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop006     Document Type: Article

References (27)

1. Yuan F, Salehi HA, Boucher Y, et al. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res. 1994;54:4564-4568.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
3. Stupp R, van den Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep. 2005;5:198-206.
4. 13C labeled anticancer agent temozolomide detected in vivo by selective cross-polarization transfer. Magn Reson Med. 1995;34:338-342.
5. Ruiz-Cabello J, Vuister GW, Moonen CTW, et al. Gradient-enhanced heteronuclear correlation spectroscopy. Theory and experimental aspects. J Magn Reson. 1992;100:282-302.
6. 13C magnetic resonance spectroscopic imaging of the intratumoral distribution of temozolomide. Magn Reson Med. 2006;55:755-761.
7. Garwood M, Ke Y. Symmetric pulses to induce arbitrary flip angles with compensation for RF inhomogeneity and resonance offsets. J Magn Reson. 1991;94:511-525.
8. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, Solaiyappan M. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia. 2001;3:143-153.
9. 30 for microvessel characterization in an intracranial glioma model. J Magn Reson Imaging. 1998;8:799-806.
10. 1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223-232.
11. Paulson ES, Schmainda KM. Comparison of dynamic susceptibilityweighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology. 2008;249:601-613.
12. Wu O, Ostergaard L, Weisskoff RM, et al. Tracer arrival timinginsensitive technique for estimating flow in MR perfusion-weighted imaging using singular value decomposition with a block-circulant deconvolution matrix. Magn Reson Med. 2003;50:164-174.
13. Belliveau JW, Rosen BR, Kantor HL, et al. Functional cerebral imaging by susceptibility-contrast NMR. Magn Reson Med. 1990;14: 538-546.
14. Dijkhuizen RM, Nicolay K. Magnetic resonance imaging in experimental models of brain disorders. J Cereb Blood Flow Metab. 2003; 23:1383-1402.
15. Kato Y, Okollie B, Raman V, et al. Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biol Ther. 2007;6:891-897.
16. Bocangel DB, Finkelstein S, Schold SC, et al. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res. 2002;8: 2725-2734.
17. Ma J, Murphy M, O'Dwyer PJ, et al. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem Pharmacol. 2002; 63:1219-1228.
18. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55:3752-3756.
19. Warmuth C, Gunther M, Zimmer C. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology. 2003;228:523-532.
20. Sun Y, Schmidt NO, Schmidt K, et al. Perfusion MRI of U87 brain tumors in a mouse model. Magn Reson Med. 2004;51:893-899.
21. 2 ) and contrast agent (MION) dose. J Magn Reson Imaging. 2003;18:397-403.
22. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol. 2006;27:859-867.
23. Donahue KM, Krouwer HG, Rand SD, et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med. 2000;43:845-853.
24. Artemov D, Solaiyappan M, Bhujwalla ZM. Magnetic resonance pharmacoangiography to detect and predict chemotherapy delivery to solid tumors. Cancer Res. 2001;61:3039-3044.
25. Smith JK, Kwock L, Castillo M. Effects of contrast material on singlevolume proton MR spectroscopy. AJNR Am J Neuroradiol. 2000;21:1084-1089.
26. Rudek MA, Donehower RC, Statkevich P, et al. Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. Pharmacotherapy. 2004;24:16-25.
27. Broniscer A, Gururangan S, MacDonald TJ, et al. Phase I trial of single-dose temozolomide and continuous administration of O6- benzylguanine in children with brain tumors: a Pediatric Brain Tumor Consortium report. Clin Cancer Res. 2007;13:6712-6718.